Sinovac Biotech (北京科兴生物制品有限公司) prospered during its Q2, thanks largely to a single $12.8 million order for its major product, the hepatitis A vaccine Healive®. Sinovac said Q2 revenues were up 21% at $20 million while net income increased a much larger 74% to $5.8 million. Sinovac reported that 89% of the $12.8 million order was filled during Q2. That means $11.4 million of the company’s $20 million in Q2 revenues derived from the one-time event. More details...

Stock Symbol: (NYSE Amex: SVA)